To date, IFFIm has provided over 20% of Gavi’s programme funding, disbursing approximately US$ 2.6 billion to support Gavi’s life-saving vaccination programmes. 

IFFIm is expected to disburse a further US$ 600 million to Gavi by the end of the 2016-2020 strategic period.

Gavi’s Impact

Thanks to Gavi’s work in the past two decades, staggering progress has been made. Child mortality is at its lowest, and today’s generation is set to be the healthiest yet. Since its inception, Gavi has protected a whole generation of children, 760 million of them, and saved over 13 million lives from potentially fatal infectious diseases.

When Gavi, the Vaccine Alliance was established in 2000, almost ten million children globally would die annually before their fifth birthday. By 2017, this number had almost halved.

IFFIm’s value to Gavi

IFFIm delivers value to Gavi by:

• increasing the funding immediately available to Gavi for life-saving vaccines
• accelerating delivery of vaccines and making funding more predictable
• giving Gavi the flexibility to use funds when and where they are needed most
• helping Gavi drive down vaccine prices and secure supply by assuring longterm funding
• empowering donors with a way to spread their contributions over future years while also having an immediate impact

Impact Highlights

Reducing vaccine costs: Pentavalent

IFFIm’s frontloaded funding model helps reduce vaccine costs and shape the market. IFFIm’s support for the pentavalent vaccine provides an example of this mechanism at work. Pentavalent is a vaccine that protects from five diseases (Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib). IFFIm funded more than 90% of the initial vaccine cost for Gavi’s pentavalent programme. This investment encouraged manufactures to increase production and decrease the price. Gavi is now able to procure pentavalent vaccines for $0.68 per dose, a price reduction of more than 75% since 2006.

Eradicating polio

IFFIm has played a critical role in the fight to end polio by providing funding that has helped slash incidence of the disease. When the Global Polio Eradication Initiative (GPEI) faced a crisis in 2006, it turned to IFFIm as the only way to finance stockpiling the polio vaccine so suppliers have it available for outbreaks. IFFIm invested US$191.28 million to help develop and license oral polio vaccine (OPV) products that could be field tested for safety and purchased in bulk. IFFIm’s support contributed to a striking 95% decline in polio cases in Nigeria and India, and an 85 % decline in type 3 polio cases globally.